EY reviewed a biopharma's AI projects against its responsible AI framework and found governance gaps.

The biopharma had no AI governance framework as regulations like the EU AI Act emerged. EY applied its Responsible AI framework to forecasting, adverse event tracking and disease detection projects. The page states the review led to minimum requirements for AI teams, better third-party risk assessment and a central AI inventory.

EY is a professional services firm that advises pharma companies on AI governance, risk and transformation

This sits in the Scale & Govern stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to monitor, govern and keep validating an AI system once it is already live in production.